| Patent application number | Description | Published |
|---|
| 20080226569 | Polyurethane dispersions for use in personal care products - The invention relates to an aqueous polyurethane dispersion suitable for use in personal care products, the dispersed polyurethane comprising the reaction products of:
| 09-18-2008 |
| 20090022678 | POLYURETHANE DISPERSIONS FOR USE IN PERSONAL CARE PRODUCTS - The invention relates to an aqueous polyurethane dispersion suitable for use in personal care products, the dispersed polyurethane comprising the reaction products of:
| 01-22-2009 |
| 20090030146 | Polyurethane dispersions for sealants - An isocyanate-terminated prepolymer having an isocyanate group content of about 2 to 7% by weight is provided. The prepolymer comprises the reaction product of a) at least one polyether diol having a number average molecular weight of 3000 to 5000; b) at least one active-hydrogen containing material having a number average molecular weight of 200 to 700 and containing two or three hydroxyl groups and optionally one carboxy group; c) at least one hydroxyalkane carboxylic acid having a number average molecular weight of less than about 200; d) optionally, a polyether monol having a number average molecular weight between 400-3,000; e) optionally, a polyether triol having a number average molecular weight of 3,000 to 9,000; and f) an aliphatic and/or cycloaliphatic diisocyanate. | 01-29-2009 |
| 20090041689 | POLYURETHANE DISPERSIONS BASED ON POLYCARBONATE POLYOLS AND SUITABLE FOR USE IN PERSONAL CARE PRODUCTS - The invention relates to a process for preparing an aqueous polyurethane dispersion suitable for use in personal care products, wherein the polyurethane is based on one or more polycarbonate polyols. | 02-12-2009 |
| Patent application number | Description | Published |
|---|
| 20090291081 | Dual-specific IL-1A/IL-1b antibodies - The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1α and human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1α and human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1α and human IL-1β. | 11-26-2009 |
| 20100266531 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 10-21-2010 |
| 20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 05-19-2011 |
